iPSCs engrafted in allogeneic hosts without immunosuppression induce donor-specific tolerance to secondary allografts

Currently, most cell or tissue transplantations using induced pluripotent stem cells (iPSCs) are anticipated to involve allogeneic iPSCs. However, the immunological properties of iPSCs in an allogeneic setting are not well understood. We previously established a mouse transplantation model of MHC-compatible/minor antigen-mismatched combinations, assuming a hypoimmunogenic iPSC-setting. Here, we found that iPSCs subcutaneously inoculated into MHC-compatible allogeneic host mice resisted rejection and formed teratomas without immunosuppressant administration. Notably, when skin grafts were transplanted onto hosts more than 40 d after the initial iPSCs inoculation, only the skin of the same strain as the initial iPSCs was engrafted. Therefore, donor-specific immune tolerance was induced by a single iPSC inoculation. Diverse analyses, including single-cell RNA-sequencing after transplantation, revealed an increase in regulatory T cell (Treg) population, particularly CD25<sup>+</sup> CD103<sup>+</sup> effector Tregs within the teratoma and skin grafts. The removal of CD25<sup>+</sup> or Foxp3<sup>+</sup> cells suppressed the increase in effector Tregs and disrupted graft acceptance, indicating the importance of these cells in the establishment of immune tolerance. Within the teratoma, we observed an increase in TGF-β2 levels, suggesting an association with the increase in effector Tregs. Our results provide important insights for future applications of allogeneic iPSC-based cell or tissue transplantation.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2025-03-12
DOI
https://doi.org/10.1073/pnas.2413398122
Citations
1
Primary Topic
Pluripotent Stem Cells Research
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

iPSCs engrafted in allogeneic hosts without immunosuppression induce donor-specific tolerance to secondary allografts

Makoto Inoue, K. Seino, Tomoki Kamatani, Satoshi Ikeda et al.
1 citations
Proceedings of the National Academy of Sciences
Pluripotent Stem Cells Research
0.81
article

iPSCs engrafted in allogeneic hosts without immunosuppression induce donor-specific tolerance to secondary allografts

Makoto Inoue, K. Seino, Tomoki Kamatani, Satoshi Ikeda, R. Kimura
article en
1 citations

Abstract

Currently, most cell or tissue transplantations using induced pluripotent stem cells (iPSCs) are anticipated to involve allogeneic iPSCs. However, the immunological properties of iPSCs in an allogeneic setting are not well understood. We previously established a mouse transplantation model of MHC-compatible/minor antigen-mismatched combinations, assuming a hypoimmunogenic iPSC-setting. Here, we found that iPSCs subcutaneously inoculated into MHC-compatible allogeneic host mice resisted rejection and formed teratomas without immunosuppressant administration. Notably, when skin grafts were transplanted onto hosts more than 40 d after the initial iPSCs inoculation, only the skin of the same strain as the initial iPSCs was engrafted. Therefore, donor-specific immune tolerance was induced by a single iPSC inoculation. Diverse analyses, including single-cell RNA-sequencing after transplantation, revealed an increase in regulatory T cell (Treg) population, particularly CD25<sup>+</sup> CD103<sup>+</sup> effector Tregs within the teratoma and skin grafts. The removal of CD25<sup>+</sup> or Foxp3<sup>+</sup> cells suppressed the increase in effector Tregs and disrupted graft acceptance, indicating the importance of these cells in the establishment of immune tolerance. Within the teratoma, we observed an increase in TGF-β2 levels, suggesting an association with the increase in effector Tregs. Our results provide important insights for future applications of allogeneic iPSC-based cell or tissue transplantation.

Proceedings of the National Academy of SciencesVol. 122(11)
Sumitomo Chemical (Japan) (JP), Hokkaido University (JP), Sumitomo Dainippon Pharma (Japan) (JP), Sumitomo Dainippon Pharma (United States) (US)
Naito Foundation, Hokkaido University, Japan Society for the Promotion of Science, Japan Science and Technology Agency
Good health and well-being
Openalex Percentile: Top 30%
Pluripotent Stem Cells Research
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.